November 30, 2021 -- BioTools Innovator is now accepting applications from startups and emerging growth companies for its second annual accelerator program. The program aims to advance innovation in life science and improve human health by accelerating the growth of best-in-class startups that are developing and commercializing biotechnology products, platforms, and services.
The four-month competition will feature 15 promising early-stage companies that are developing research tools and services for biotechnology, biomedicine, cell biology, molecular biology, genetics, and biochemistry from around the globe. BioTools Innovator will provide these companies with customized education, mentorship, and funding opportunities, leveraging the MedTech Innovator Accelerator model.
Applicants will progress through multiple rounds of consideration, where they will have increasing exposure to industry stakeholders. Applications are now being accepted and will close on January 31, 2022.
During the first round of evaluation, expert reviewers will score online applications and determine up to 60 of the highest-scoring startups. The initial candidates selected will present at one of several virtual and in-person pitch events that will take place beginning in March 2022 and lasting through May 2022. After further consideration, 15 companies will advance to receive a slot in the BioTools Innovator 2022 cohort and participate in the virtual accelerator.
The BioTools Innovator final competition will be held in October 2022. Up to $250,000 in nondilutive cash prizes and in-kind services will be awarded to the four selected finalists. The grand prize winner will be determined via a live audience vote and announced during the event.
Funding to launch BioTools Innovator program was provided by the Frederick Gardner Cottrell Foundation of Research Corporation Technologies.
BioTools Innovator is holding a virtual information session on December 9, 2021.
Do you have a unique perspective on your research related to BioTools Innovator? Contact the editor today to learn more.